Smallpox vaccine - Therion Biologics

Drug Profile

Smallpox vaccine - Therion Biologics

Alternative Names: TBC-MVA

Latest Information Update: 03 Apr 2007

Price : $50

At a glance

  • Originator Therion Biologics
  • Developer National Institutes of Health (USA); Therion Biologics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 24 Dec 2002 Phase-I clinical trials in Smallpox in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top